⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Resmetirom (Rezdiffra) (resmetirom) | Accelerate Your Fibrosis Research

Home/Drugs/Resmetirom (Rezdiffra)

Resmetirom (Rezdiffra)

resmetirom

Approved

Sponsor: Madrigal Pharmaceuticals

Indication: MASH

Mechanism of Action

Thyroid hormone receptor beta (THR-β) selective agonist

Target: THR-β

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

ACTIVE_NOT_RECRUITINGNCT07216313

A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants

Phase:PHASE1Org:Sagimet Biosciences Inc.

COMPLETED

Relevant Publications (PubMed)

SLC11A1 protein as a key regulator of iron metabolism, ferroptosis mediator, and putative therapeutic target in nonalcoholic fatty liver disease: an integrated bioinformatics analysis.

Wang Y, Zhou B, Li S et al.

Front Pharmacol2025

Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends.

Zacharia GS, Ashraf MH, Sosa F et al.

World J Gastrointest Pharmacol Ther2025 Dec 5

Screening and management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Geary A

JAAPA2025 Dec 10

Meta-analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis (MASH).

Validated Models

This drug has been validated in the following preclinical models:

NCT03220165

Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196

Phase:PHASE1Org:Madrigal Pharmaceuticals, Inc.

RECRUITINGNCT07249788

Resmiterom Efficacy & Safety in Patients With MASH

Phase:PHASE4Org:Nabiqasim Industries (Pvt) Ltd

COMPLETEDNCT01367873

Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects

Phase:PHASE1Org:Madrigal Pharmaceuticals, Inc.

COMPLETEDNCT02542969

Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin

Phase:PHASE1Org:Madrigal Pharmaceuticals, Inc.

View all trials on ClinicalTrials.gov

Wood E, Akande R, Iqbal I et al.

Diabetes Obes Metab2025 Dec 9

Optimized MASH Treatment Eligibility Cutoffs for MRE-measured Liver Stiffness and Proton Density Fat Fraction.

Owusu N, Kalutkiewicz K, Li J et al.

Clin Mol Hepatol2025 Dec 8

View more on PubMed